NYSEAMERICAN:PTN - Palatin Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.7898 +0.01 (+1.28 %) (As of 02/18/2019 06:49 AM ET)Previous Close$0.7829Today's Range$0.7806 - $0.8152-Week Range$0.59 - $1.59Volume960,677 shsAverage Volume640,888 shsMarket Capitalization$160.38 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey. Receive PTN News and Ratings via Email Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PTN Previous SymbolNYSE:PTN CUSIPN/A Webwww.palatin.com Phone+1-609-4952200Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees19 Outstanding Shares203,063,000Market Cap$160.38 million OptionableNot Optionable Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions What is Palatin Technologies' stock symbol? Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN." How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings data on Tuesday, February, 12th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.00. During the same quarter in the prior year, the business earned $0.01 earnings per share. View Palatin Technologies' Earnings History. When is Palatin Technologies' next earnings date? Palatin Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Palatin Technologies. What price target have analysts set for PTN? 2 Wall Street analysts have issued 12 month price targets for Palatin Technologies' shares. Their predictions range from $3.00 to $5.00. On average, they expect Palatin Technologies' share price to reach $4.00 in the next year. This suggests a possible upside of 406.5% from the stock's current price. View Analyst Price Targets for Palatin Technologies. What is the consensus analysts' recommendation for Palatin Technologies? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies. What are Wall Street analysts saying about Palatin Technologies stock? Here are some recent quotes from research analysts about Palatin Technologies stock: 1. According to Zacks Investment Research, "Palatin Technologies, Inc is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies. " (2/16/2019) 2. HC Wainwright analysts commented, "Our thesis on shares remains unchanged; major boxes checked and valuation disconnect exists, in our belief. Significant boxes have already been checked off, which we believe provide a derisked opportunity for investors." (1/11/2019) Has Palatin Technologies been receiving favorable news coverage? News articles about PTN stock have trended neutral recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Palatin Technologies earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Are investors shorting Palatin Technologies? Palatin Technologies saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 14,228,922 shares, an increase of 5.3% from the January 15th total of 13,514,447 shares. Based on an average daily volume of 525,865 shares, the days-to-cover ratio is currently 27.1 days. Approximately 7.4% of the company's stock are sold short. View Palatin Technologies' Current Options Chain. Who are some of Palatin Technologies' key competitors? Some companies that are related to Palatin Technologies include Senseonics (SENS), Senseonics (SENS), Profound Medical (PRN), Lexagene (LXG), Sernova (SVA), Smiles Inclusive (SIL), LED Medical Diagnostics (LMD), SQI Diagnostics (SQD), Dorsavi (DVL), VentriPoint Diagnostics (VPT), GeneNews (GEN), 3D Signatures (DXD), Imaging Dynamics (IDL), Med Biogene (MBI) and BioMark Diagnostics (BUX). Who are Palatin Technologies' key executives? Palatin Technologies' management team includes the folowing people: Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 65)Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 57)Mr. Stephen T. Wills CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 62)Burns McClellan, VP of Investor Relations Who are Palatin Technologies' major shareholders? Palatin Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.20%), Acadian Asset Management LLC (1.18%), Northern Trust Corp (1.15%), Bank of New York Mellon Corp (0.35%), Strs Ohio (0.32%) and Rhumbline Advisers (0.12%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris and Stephen T Wills. View Institutional Ownership Trends for Palatin Technologies. Which institutional investors are selling Palatin Technologies stock? PTN stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, BlackRock Inc. and Strs Ohio. View Insider Buying and Selling for Palatin Technologies. Which institutional investors are buying Palatin Technologies stock? PTN stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Rhumbline Advisers and Northern Trust Corp. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris and Stephen T Wills. View Insider Buying and Selling for Palatin Technologies. How do I buy shares of Palatin Technologies? Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Palatin Technologies' stock price today? One share of PTN stock can currently be purchased for approximately $0.7898. How big of a company is Palatin Technologies? Palatin Technologies has a market capitalization of $160.38 million. Palatin Technologies employs 19 workers across the globe. What is Palatin Technologies' official website? The official website for Palatin Technologies is http://www.palatin.com/. How can I contact Palatin Technologies? Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200. MarketBeat Community Rating for Palatin Technologies (NYSEAMERICAN PTN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 289 (Vote Outperform)Underperform Votes: 222 (Vote Underperform)Total Votes: 511MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2019 by MarketBeat.com StaffFeatured Article: Why do companies issue stock splits?